Sign inJoin waitlistJoin the waitlist

Jonathan Wickiser

Associate Professor at UT Southwestern Medical Center · Children's Health Andrews Institute

Credentials: · · ·

History

Children's Health Andrews Institute
Present
University of Texas Southwestern Medical Center
Present

Pediatric Hematology Oncology
University of Texas Southwestern Medical Center
2003–2006
Pediatrics
University of Virginia Medical Center
1999–2000
Texas Tech University Health Sciences Center School of Medicine
1995–1999
Southern Methodist University
1991–1995

Research

Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours
Nature Communications · 2014 · 199 citations
A comparison of pediatric, adolescent, and adult testicular germ cell malignancy
Pediatric Blood & Cancer · 2014 · 46 citations
Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 38 citations

Nicholas Cost
8 papers
Linda Baker
7 papers
Dinesh Rakheja
6 papers
Candice Granberg
5 papers · 5 as a fellow
JL
Jessica Lubahn
5 papers · 3 as a resident
Patricio Gargollo
5 papers · 5 as a fellow
Vitaly Margulis
5 papers
AS
Arthur Sagalowsky
3 papers
GR
Ganesh Raj
3 papers
Adam Romman
2 papers · 2 as a resident
Amy Walz
2 papers
Bruce Schlomer
2 papers · 2 as a fellow

Clinical trials

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Site PI · Recruiting · Phase 2
Children's Oncology Group
2020–2027
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Site PI · Recruiting · Phase 3
Children's Oncology Group
2017–2027
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Site PI · Recruiting · Phase 3
University of Sydney
2014–2029
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Sub-investigator · Recruiting · Phase 2
Healx Limited
2025–2028